Noam Solomon is the founder of Immunai. Immunai has raised $300M in total funding. Latest round: Series B. Based in New York, United States.
Noam Solomon is the CEO and co-founder of Immunai, a company focused on decoding and mapping the human immune system to enhance disease detection, diagnosis, and treatment. He utilizes single-cell technologies, immunology, pathology, and machine learning to construct a large dataset of clinical immunological data. Solomon has secured nearly $300 million in funding to advance Immunai's goal of reprogramming the immune system for drug development.
Full founder directory · Investor directory · Company funding database · Fundraising library